Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities
- PMID: 15661408
- DOI: 10.1016/j.eururo.2004.09.007
Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities
Abstract
Objectives: This review aims to provide practising clinicians with the most recent knowledge of the biological nature of prostate cancer (PC) to facilitate investigation of new treatment modalities for patients with PC, especially the hormone-refractory state of the disease.
Methods: Review of the literature using PubMed search and scientific journal publications.
Results: Much progress has been made towards an understanding of the development and progression of PC, and the factors which drive the development of androgen independence. Neuroendocrine (NE) cells may provide an intriguing link between NE cell differentiation and tumour progression in PC with the genetically supported formation of androgen-independent clones which regulate the proliferation of neighbouring non-NE-phenotype cancer cells in a paracrine manner by secretion of NE products. Various NE peptides stimulate proliferation of androgen-independent PC through transactivation of the androgen receptors (AR). Therefore, cancerous epithelial cells that increase their responsiveness to NE factors or induce NE cells to release trophic factors may have a survival advantage over their siblings.
Conclusion: This review shows the need to improve our understanding of the biological nature of PC, especially cancer cells of the NE phenotype and their regulatory products to develop new therapeutic protocols and trials based on NE hormones and their agonists/antagonists.
Similar articles
-
Neuroendocrine differentiation in prostate cancer: from lab to bedside.Urol Int. 2007;79(4):287-96. doi: 10.1159/000109711. Urol Int. 2007. PMID: 18025844 Review.
-
Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.Cancer Res. 2000 Feb 1;60(3):741-8. Cancer Res. 2000. PMID: 10676662
-
Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.G Chir. 2010 Nov-Dec;31(11-12):568-74. G Chir. 2010. PMID: 21232206
-
The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.J Endocrinol Invest. 2005;28(11 Suppl International):141-5. J Endocrinol Invest. 2005. PMID: 16625864 Review.
-
Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.Oncogene. 2008 Jan 17;27(4):506-18. doi: 10.1038/sj.onc.1210656. Epub 2007 Jul 16. Oncogene. 2008. PMID: 17637748
Cited by
-
Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma.PLoS One. 2013 Apr 19;8(4):e61848. doi: 10.1371/journal.pone.0061848. Print 2013. PLoS One. 2013. PMID: 23620793 Free PMC article.
-
Beta-adrenergic signaling on neuroendocrine differentiation, angiogenesis, and metastasis in prostate cancer progression.Asian J Androl. 2019 May-Jun;21(3):253-259. doi: 10.4103/aja.aja_32_18. Asian J Androl. 2019. PMID: 29848834 Free PMC article. Review.
-
Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer.Commun Biol. 2020 Dec 16;3(1):778. doi: 10.1038/s42003-020-01476-1. Commun Biol. 2020. PMID: 33328604 Free PMC article.
-
Smoothened loss is a characteristic of neuroendocrine prostate cancer.Prostate. 2021 Jun;81(9):508-520. doi: 10.1002/pros.24122. Epub 2021 May 6. Prostate. 2021. PMID: 33955576 Free PMC article.
-
Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway.Endocr Relat Cancer. 2012 May 24;19(3):321-31. doi: 10.1530/ERC-11-0368. Print 2012 Jun. Endocr Relat Cancer. 2012. PMID: 22389383 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials